@article{APS4277,
author = {Jie Wang and Yu-qian Bao and Cheng Hu and Rong Zhang and Cong-rong Wang and Jun-xi Lu and Wei-ping Jia and Kun-san Xiang},
title = {Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients},
journal = {Acta Pharmacologica Sinica},
volume = {29},
number = {2},
year = {2016},
keywords = {},
abstract = {Aim: The aim of the present study was to investigate the relationship between R219K, M883I, and R1587K variants of the ATP-binding cassette transporter subfamily A number 1 (ABCA1) gene and response to rosiglitazone treatment in newly diagnosed patients with type 2 diabetes.
Methods: A total of 105 diabetic patients with no history of antihyperglycemia medication were treated with rosiglitazone (4 or 8 mg daily) for 48 weeks. Three non-synonymous variants R219K, M883I, and R1587K, were genotyped in all patients.
Results: Ninety-three patients completed the entire study. The R219K variant of ABCA1 had an effect on rosiglitazone response with the per-allele odds ratio of 2.04 for treatment failure (P},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/4277}
}